✦ LIBER ✦

Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer

✍ Scribed by O'Reilly, Susan M.; Camplejohn, Richard S.; Millis, Rosemary R.; Rubens, Robert D.; Richards, Michael A.

Book ID: 123524725
Publisher: Elsevier Science
Year: 1990
Weight: 529 KB
Volume: 26
Category: Article
ISSN: 0277-5379
DOI: 10.1016/0277-5379(90)90045-U

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomised trial: survival benefit and s

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer

✍ Kümmel, S; Krocker, J; Kohls, A; Breitbach, G-P; Morack, G; Budner, M; Blohmer, 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 154 KB

Randomised Trial: Survival Benefit and S

Randomised Trial: Survival Benefit and Safety of Adjuvant Dose-dense Chemotherapy for Node-positive Breast Cancer

✍ McArthur, H.L.; Hudis, C.A. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 94 KB

Adjuvant Radiotherapy and Chemotherapy i

Adjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast Cancer

✍ Ragaz, Joseph; Jackson, Stewart M.; Le, Nhu; Plenderleith, Ian H.; Spinelli, Joh 📂 Article 📅 1997 🏛 Massachusetts Medical Society 🌐 English ⚖ 95 KB

Protein expression, survival and docetax

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

✍ Jocelyne Jacquemier; Jean-Marie Boher; Henri Roche; Benjamin Esterni; Daniel Ser 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 339 KB

Adjuvant trastuzumab with chemotherapy i

Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer

✍ Heather L. McArthur; Kathleen M. Mahoney; Patrick G. Morris; Sujata Patil; Linds 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB 👁 1 views

## Abstract ## BACKGROUND: Several large, randomized trials established the benefits of adjuvant trastuzumab with chemotherapy. However, the benefit for women with small, node‐negative HER2‐positive (HER2+) disease is unknown, as these patients were largely excluded from these trials. Therefore, a

Racial and socioeconomic disparities in

Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer

✍ Alessia Bhargava; Xianglin L. Du 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views